Investor's Business Daily on MSN
Pfizer targets monthly obesity shot. Why Lilly could still have the weight-loss heavyweight.
An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results